Project Grant R21HD117763
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $303K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This $420,000 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Myogene Bio LLC, a woman-owned small biotechnology company, to evaluate the efficacy of CRISPR gene editing technology in treating Duchenne muscular dystrophy (DMD). The research aims to correlate CRISPR efficacy with functional outcomes in preclinical DMD models, building on the company's previous federal grant awards focused...
- This $499,300 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research by Myogene Bio LLC, a woman-owned small business in San Diego, California, to advance manufacturing and release testing of a gene editing therapy for Duchenne muscular dystrophy (DMD). The key products and services to be delivered include: 1) Optimizing the upstream...
- This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $692,292.00 to the Children's Research Institute in Washington, D.C. to conduct research aimed at understanding the regulation of pediatric regenerative myogenesis and its implications for muscle disease. The key products and services to be delivered under this 5-year award...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $295,294 Phase I SBIR project grant (CFDA 93.846) to Gigamune, Inc. to develop a novel lentiviral gene delivery platform for in vivo delivery of the full-length dystrophin gene to muscle cells. The goal is to create an efficient and targeted approach for gene therapy to treat Duchenne muscular dystrophy, a severe genetic disorder causing muscle wasting. The project aims to leverage Gigamune's...
- This $306,872 Project Grant awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under CFDA 93.846 is supporting Vivreon Biosciences, LLC, a life sciences company in San Diego, California, to develop a novel small molecule therapeutic targeting the ORAI1 calcium channel for treating Duchenne muscular dystrophy (DMD) and other dystrophinopathies. The key objectives of this 2-year project are to assess the toxicity profile of the therapeutic candidate and...
- The National Institute of Child Health and Human Development (NICHD) awarded a Project Grant of $107,948 to New York University (NYU) on June 20, 2025 under the Child Health and Human Development Extramural Research (CFDA 93.865) program. The grant aims to enhance the understanding of motor neuron differentiation, which is critical for addressing spinal muscular atrophy and amyotrophic lateral sclerosis - neurological disorders affecting nearly 1 in 10,000 people globally. The research will...
- This federal Project Grant award, with $405,341 in funding from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420), supports research by the Children's Research Institute to explore the use of pro-resolution and restorative pharmacology approaches for the treatment of Duchenne muscular dystrophy (DMD). The 3-year project, running from August 1, 2025 to July 31, 2028, aims to develop innovative medical solutions to address this critical health challenge...
- This $687,427 Project Grant awarded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the Federal Grant Program 93.865 - Child Health and Human Development Extramural Research, aims to investigate the role of macrophages in guiding digit regeneration. The project leverages a comparative mouse model of bone regeneration and scar formation to study a unique population of macrophages that associates with growing bone and expresses growth factors...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is focused on developing a novel nanovesicle-based therapy for myotonic dystrophy type 1 (DM1), a common adult-onset muscular dystrophy. The $306,859 award supports a two-phase effort to validate interfering RNA-loaded nanovesicles that can selectively modulate the toxic DMPK mRNA responsible for...
- The U.S. Defense Health Agency awarded a $777,659 Project Grant to the Children's Research Institute in Washington, DC under the Military Medical Research and Development program (CFDA 12.420). The grant funding, which covers the period from August 1, 2025 to July 31, 2028, will support the institute's research on the use of pro-resolution and restorative pharmacology approaches for the treatment of Duchenne muscular dystrophy (DMD). As a non-profit pediatric research organization, the...